Skip to main content

Table 3 Adverse events in the treated population

From: A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations – results of a prematurely terminated study

 

Vancomycin (n = 7)

Daptomycin (n = 7)

All (n = 14)

Serious adverse eventsa

4

3

7

Adverse events

   

Cardiac arrhythmia

2

1

3

General cardiacb

2

1

3

Constitutional symptomsc

0

2

2

Dermatologicd

3

0

3

Adrenal insufficiency

0

1

1

Eosinophilia

0

1

1

Fall

1

1

2

Nausea and vomiting

0

1

1

Anemia

1

1

2

Infectione

3

4

7

Neurologicalf

2

1

3

Pain

2

1

3

Hematuria

0

1

1

  1. Data are number of cases
  2. aIn the vancomycin arm this included intracranial hemorrhage, catheter-related infection, acute coronary syndrome and vascular access complication. In the daptomycin arm this included catheter-related infection and hypotension
  3. bIncluding adverse events termed “acute coronary event”, “hypotension”, and “pulmonary edema”
  4. cIncluding events termed “somnolence” and “fever”
  5. dIncluding events termed “rash-maculopapular” and “pruritus”
  6. eIncluding events termed “catheter-related infection” and “urinary tract infection”
  7. fIncluding events termed “seizure”, “intracranial hemorrhage”, and “dizziness”